People: Transition Therapeutics Inc (TTH.TO)
3.00CAD
17 May 2013
$0.10 (+3.45%)
$2.90
$2.85
$3.00
$2.85
3,527
4,714
$3.72
$1.74
Connop, Bruce
Brief Biography
Dr. Bruce Connop is Vice President - Non-Clinical & Pharmaceutical Development of Transition Therapeutics Inc. He has been with Transition since 2006 and served as Sr. Director, Nonclinical Drug Development until he was appointed VP, Non-Clinical & Pharmaceutical Development in 2012. With his experience in pharmacology, toxicology and manufacturing he is responsible for a broad range of activities and has made contributions to the advancement of pipeline products. Dr. Connop holds a Ph.D. from Queen’s University and has had experience at other biotech and pharmaceutical companies.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 165,154 | -- | 73,230 | 238,384 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Tony Cruz |
746,279 |
Nicole Rusaw-George |
298,627 |
Bruce Connop |
238,384 |
Aleksandra Pastrak |
391,325 |
Carl Damiani |
308,451 |
Louis Alexopoulos |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
